Moleculo

First Investment: 2015

EXIT - Acquisition (Illumina: ILMN)

Moleculo’s founders developed new library prep and analysis techniques that allowed them to assemble short sequences of DNA base-pair information into accurate, synthetic long reads. Illumina acquired the company in 2013.

Explore Companies

DVLP Medicines

Creating a software co-pilot for drug development and a new marketplace for investors and outsourced R&D and manufacturing

Noetik

Using self-supervised machine learning to map the circuit diagram of tumor biology and develop new immunotherapies for cancer

Solu Therapeutics

Advancing precision medicine by combining the efficacy of antibodies with the binding ability of small molecules

Visolis

Using synthetic biology to manufacture carbon-negative materials